Cyclofenil: Difference between revisions
No edit summary |
m (Protected "Cyclofenil": Bot: Protecting all pages from category Drug ([Edit=Allow only administrators] (indefinite) [Move=Allow only administrators] (indefinite))) |
||
| (One intermediate revision by one other user not shown) | |||
| Line 6: | Line 6: | ||
==Overview== | ==Overview== | ||
'''Cyclofenil''' ([[International Nonproprietary Name|INN]], trade names '''Ondogyne''', '''Sexovid''', and others) is a [[selective estrogen receptor modulator]]. | '''Cyclofenil''' ([[International Nonproprietary Name|INN]], trade names '''Ondogyne''', '''Sexovid''', and others) is a [[selective estrogen receptor modulator]]. | ||
It was investigated as a possible treatment for [[scleroderma]] in the 1980s, but was found to be ineffective.Later study of its efficacy in treating [[Raynaud's phenomenon]] in people with scleroderma also found no [[statistical significance|statistically significant]] benefit. | |||
It was investigated as a possible treatment for [[scleroderma]] in the 1980s, but was found to be ineffective. | |||
==References== | ==References== | ||
Latest revision as of 19:28, 18 August 2015
|
WikiDoc Resources for Cyclofenil |
|
Articles |
|---|
|
Most recent articles on Cyclofenil |
|
Media |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Cyclofenil at Clinical Trials.gov Clinical Trials on Cyclofenil at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Cyclofenil
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Cyclofenil Discussion groups on Cyclofenil Patient Handouts on Cyclofenil Directions to Hospitals Treating Cyclofenil Risk calculators and risk factors for Cyclofenil
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Cyclofenil |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Cyclofenil (INN, trade names Ondogyne, Sexovid, and others) is a selective estrogen receptor modulator. It was investigated as a possible treatment for scleroderma in the 1980s, but was found to be ineffective.Later study of its efficacy in treating Raynaud's phenomenon in people with scleroderma also found no statistically significant benefit.